Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by Hemenway Trust Co LLC

Hemenway Trust Co LLC raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,773 shares of the biopharmaceutical company’s stock after buying an additional 3,373 shares during the period. Hemenway Trust Co LLC’s holdings in Alnylam Pharmaceuticals were worth $628,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the company. KCG Holdings Inc. raised its position in Alnylam Pharmaceuticals by 74.3% in the third quarter. KCG Holdings Inc. now owns 25,056 shares of the biopharmaceutical company’s stock valued at $1,698,000 after buying an additional 10,679 shares during the last quarter. BlackRock Fund Advisors raised its position in Alnylam Pharmaceuticals by 3.0% in the third quarter. BlackRock Fund Advisors now owns 1,927,337 shares of the biopharmaceutical company’s stock valued at $130,635,000 after buying an additional 56,455 shares during the last quarter. California State Teachers Retirement System raised its position in Alnylam Pharmaceuticals by 0.9% in the third quarter. California State Teachers Retirement System now owns 160,290 shares of the biopharmaceutical company’s stock valued at $10,864,000 after buying an additional 1,400 shares during the last quarter. DIAM Co. Ltd. raised its position in Alnylam Pharmaceuticals by 25.5% in the third quarter. DIAM Co. Ltd. now owns 56,343 shares of the biopharmaceutical company’s stock valued at $3,935,000 after buying an additional 11,465 shares during the last quarter. Finally, TimesSquare Capital Management LLC raised its position in Alnylam Pharmaceuticals by 8.7% in the third quarter. TimesSquare Capital Management LLC now owns 195,800 shares of the biopharmaceutical company’s stock valued at $13,271,000 after buying an additional 15,600 shares during the last quarter. Institutional investors and hedge funds own 88.70% of the company’s stock.

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded up 0.09% during trading on Monday, hitting $45.61. 832,970 shares of the company were exchanged. The stock’s market capitalization is $3.92 billion. Alnylam Pharmaceuticals, Inc. has a 1-year low of $31.38 and a 1-year high of $80.11. The company has a 50 day moving average of $40.56 and a 200-day moving average of $51.95.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.02. The company had revenue of $17.50 million for the quarter, compared to the consensus estimate of $10.66 million. Alnylam Pharmaceuticals had a negative return on equity of 37.25% and a negative net margin of 869.63%. The firm’s quarterly revenue was up 130.3% on a year-over-year basis. During the same quarter last year, the company earned ($1.07) EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.01) earnings per share for the current year.

“Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by Hemenway Trust Co LLC” was first reported by sleekmoney and is the property of of sleekmoney. If you are accessing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at http://sleekmoney.com/alnylam-pharmaceuticals-inc-alny-shares-bought-by-hemenway-trust-co-llc/1659081.html.

Several research analysts have issued reports on ALNY shares. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a report on Tuesday, October 25th. FBR & Co restated a “buy” rating and set a $100.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, November 3rd. Needham & Company LLC reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, December 6th. Cowen and Company reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 3rd. Finally, Vetr lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $46.77 price objective for the company. in a research note on Monday, February 6th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $62.83.

In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $37.83, for a total value of $567,450.00. Following the sale, the director now owns 155,795 shares of the company’s stock, valued at approximately $5,893,724.85. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Akshay Vaishnaw sold 29,165 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, November 30th. The stock was sold at an average price of $44.99, for a total value of $1,312,133.35. Following the completion of the sale, the chief marketing officer now directly owns 34,915 shares in the company, valued at approximately $1,570,825.85. The disclosure for this sale can be found here. Insiders have sold a total of 59,165 shares of company stock worth $2,448,833 in the last three months. 4.00% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).

5 Day Chart for NASDAQ:ALNY

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/alnylam-pharmaceuticals-inc-alny-shares-bought-by-hemenway-trust-co-llc/1659081.html

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *